Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1316 • ACR Convergence 2023
Influence of Rheumatoid Factor on Serum Drug Levels of TNF Inhibitors with Different Structures in Rheumatoid Arthritis
Ana Martinez Feito¹, Chamaida Plasencia-Rodríguez², Marta Novella-Navarro², Johanna E. Gehin³, Borja Hernandez-Breijo⁴, Claudia M.Brenis⁵, Alejandro Villalba⁶, Elisa Fernandez-Fernandez⁴, Irene Monjo⁷, Dora Pascual-Salcedo⁸, Pilar Nozal⁹ and Alejandro Balsa², ¹Immuno-Rheumatology research group , Institute for Health Research (IdiPAZ), Madrid, Spain, ²Hospital Universitario La Paz, Madrid, Spain, ³Dept. of Medical Biochemistry, Oslo University Hospital, Oslo, Norway, ⁴La Paz University Hospital, Madrid, Spain, ⁵VIB-UGent Inflammation Research Center Gent, Belgium, Gent, Belgium, ⁶Rheumatology Department, La Paz University Hospital, Madrid, Spain, ⁷University Hospital La Paz, Madrid, Spain, ⁸Immuno-Rheumatology Research Group, La Paz University Hospital, Madrid, Spain, ⁹Immunology Unit in La Paz University Hospital-Idipaz, Madrid, Spain
Background/Purpose: Elevated rheumatoid factor (RF) in patients with rheumatoid arthritis (RA) is associated with higher disease activity. A significantly lower efficacy of TNF inhibitors (TNFi)…
Abstract Number: 1333 • ACR Convergence 2023
Rheumatoid Arthritis-associated Lymphoproliferative Disorders: A Multi-center Analysis of Clinical Outcomes and Evaluation of Anti-rheumatic Drugs After LPD Onset
YOSHIHIKO HOSHIDA¹, Atsuko Tsujii², SHIRO OHSHIMA³, YUKIHIKO SAEKI³, MASATO YAGITA⁴, TOMOYA MIYAMURA⁵, Masao Katayama⁶, TOMONORI KAWASAKI⁷, YASUSHI HIRAMATSU⁸, Hisaji Oshima⁹, TOSHIHIKO MURAYAMA¹⁰, SHINJI HIGA¹¹, KAZUYA KURAOKA¹², FUMINORI HIRANO¹³, KENJI ICHIKAWA¹⁴, MITSUTOSHI KUROSAWA¹⁵, HIROAKI SUZUKI¹⁵, NORIYUKI CHIBA¹⁶, TAKAO SUGIYAMA¹⁷, YUKO MINAMI¹⁸, HITOSHI NIINO¹⁹, ATSUSHI IHATA²⁰, IKUO SAITO²¹, AKIKO MITSUO²², TOSHITAKA MAEJIMA²³, ATSUHIRO KAWASHIMA²⁴, HIROSHI TSUTANI²⁵, KOICHIRO TAKAHI²⁶, TAKAHIKO KASAI²⁷, YOKO SHINNO²⁸, YOSHIRO TACHIYAMA²⁹, NORIHIRO TERAMOTO³⁰, KENICHI TAGUCHI³¹, SHINJI NAITO³², SHIGERU YOSHIZAWA³³, MASAHIRO ITO³⁴, YASUO SUENAGA³⁵, Shunsuke Mori³⁶, SHOICHI NAGAKURA³⁷, NORIE YOSHIKAWA³⁸, MITSUHARU NOMOTO³⁹, ATSUHISA UEDA⁴⁰, SHOUHEI NAGAOKA⁴¹, YUKIO TSUURA⁴², KEIGO SETOGUCHI⁴³, SHOJI SUGII⁴⁴, Asami Abe⁴⁵, TOSHIAKI SUGAYA⁴⁶, HIROYUKI SUGAHARA⁴⁷, MASAHIRO KOSETO⁴⁸, YASUO KUNUGIZA², NORISHIGE IIZUKA³, RYOSUKE YOSHIHARA⁴, HIROKI YABE⁵, TOMOAKI FUJISAKI⁶, EIICHI MORII⁷, MORISHIGE TAKESHITA⁸, MASAKAZU SATO⁹, KAZUYOSHI SAITO¹⁰, Kiyoshi Matsui¹¹, YASUHIKO TOMITA¹², HIROSHI FURUKAWA¹³ and Shigeto Tohma¹⁴, ¹National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan, ²Osaka Minami Medical Center, Kawachinagano City, Japan, ³National Hospital Organization (NHO), Osaka Minami Medical Center, Kawachinagano, Japan, ⁴Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-kofukai, Osaka, Japan, ⁵NHO Kyushu Medical Center, Fukuoka, Japan, ⁶National Hospital Organization, Nagoya Medical Center, Nagoya, JP, Nagoya, Japan, ⁷NHO Nagoya Medical Center, Nagoya, Japan, ⁸Japanese Red Cross Society Himeji Hospital, Himeji, Japan, ⁹National Tokyo Medical Center, Tokyo, Japan, ¹⁰NHO Kumamoto Medical Center, Kumamoto, Japan, ¹¹Daini Osaka Police Hospital, Osaka, Japan, ¹²NHO Kure Medical Center /Chugoku Cancer Center, Kure, Japan, ¹³NHO Asahikawa Medical Center, Asahikawa, Japan, ¹⁴Nissei hospital, Sapporo, Japan, ¹⁵NHO Hokkaido Cancer Center, Sapporo, Japan, ¹⁶NHO Morioka Medical Center, Morioka, Japan, ¹⁷NHO Shimoshizu Hospital, Yotsukaido, Japan, ¹⁸NHO Ibarakihigashi Hospital, Ibaraki, Japan, ¹⁹NHO Yokohama Medical Center, Yokohama, Japan, ²⁰National Hospital Organization Yokohama Medical Center, Yokohama, Japan, ²¹NHO Sagamihara Hospital, Sagamihara, Japan, ²²NHO Disaster Medical Center, Tachikawa, Japan, ²³NHO Shinshu Ueda Medical Center, Ueda, Japan, ²⁴NHO Kanazawa Medical Center, Kanazawa, Japan, ²⁵NHO Awara Hospital, Awara, Japan, ²⁶NHO Osaka Toneyama Medical Center, Toyonaka, Japan, ²⁷Japan Red Cross Society Tokushima Hospital, Komatsushima, Japan, ²⁸NHO Okayama Medical Center, Okayama, Japan, ²⁹NHO Hiroshima Nishi Medical Center, Otake, Japan, ³⁰NHO Shikoku Cancer Center, Matsuyama, Japan, ³¹NHO Kyushu Cancer Center, Fukuoka, Japan, ³²NHO Ureshino Medical Center, Ureshino, Japan, ³³NHO Fukuoka Hospital, Fukuoka, Japan, ³⁴NHO Nagasaki Medical Center, Omura, Japan, ³⁵NHO Beppu Medical Center, Beppu, Japan, ³⁶NHO Kumamoto Saishun Medical Center, Koshi, Japan, ³⁷NHO Kumamoto Minami Hospital, Uki, Japan, ³⁸NHO Miyakonojo Medical Center, Miyakonojo, Japan, ³⁹NHO Kagoshima Medical Center, Kagoshima, Japan, ⁴⁰Yokohama City University Medical Center, Yokohama, Japan, ⁴¹Yokohama Minami Kyosai Hospital, Yokohama, Japan, ⁴²Department of Pathology Yokosuka Kyosai Hospital, Yokosuka, Japan, ⁴³Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital / Tokyo Metropolitan Komagome Hospital, Tokyo, Japan, ⁴⁴Tokyo Metropolitan Matsuzawa Hospital, Tokyo, Japan, ⁴⁵Niigata Rheumatic Center, Shibata, Japan, ⁴⁶Fuchu Hospital, Izumi, Japan, ⁴⁷Sumitomo Hospital, Osaka, Japan, ⁴⁸Nippon Life Hospital, Osaka, Japan, ⁴⁹JCHO Hoshigaoka Medical Center, Hirakata, Japan, ⁵⁰Kishiwada City Hospital, Kishiwada, Japan, ⁵¹Hyogo Prefectural Kakogawa Hospital, Kakogawa, Japan, ⁵²Ako Central Hospital, Ako, Japan, ⁵³Matsuyama Red Cross Hospital, Matsuyama, Japan, ⁵⁴Osaka University, Suita, Japan, ⁵⁵Fukuoka University, Fukuoka, Japan, ⁵⁶Kurashiki University of Science and the Arts, Kurashiki, Japan, ⁵⁷University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵⁸Hyogo Medical University, Nishinomiya, Japan, ⁵⁹International University of Health and Welfare, Otawara City, Japan, ⁶⁰NHO Tokyo National Hospital, Kiyose, Japan, ⁶¹NHO Tokyo National Hospital, Dallas, TX
Background/Purpose: The largest multi-center collaborative study on lymphoproliferative disorders (LPD) in rheumatoid arthritis (RA) (RA-LPD) in Japan was conducted to characterize its clinical outcomes and…
Abstract Number: 1359 • ACR Convergence 2023
Association of Menstrual Cycles and Disease Flare Activity in Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Lucy Masto¹, Amaya Smole¹, Caroline Siegel¹, Sarah Lieber², Sanjana Adurty³, Jonah Levine¹, Bessie Stamm¹, Lisa Mandl², Michael Lockshin², Lisa Sammaritano² and Medha Barbhaiya², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Weill Cornell Medical College, New York, NY
Background/Purpose: Whether the timing of menstruation impacts disease activity or severity among women with SLE or RA is poorly understood. We evaluated systemic rheumatic disease…
Abstract Number: 1679 • ACR Convergence 2023
Effects of Janus Kinase Inhibitor on TNF-a and IL-6-Induced Osteoclasts and RANKL-Induced Osteoclasts in Peripheral Blood Monocytes from Patients with Rheumatoid Arthritis
Kazuhiro Yokota¹, Yoshimi Aizaki², Takuma Tsuzuki Wada¹, Hiroshi Kajiyama¹, Yasuto Araki², Hiroaki Yazawa², Yuji Akiyama² and Toshihide Mimura¹, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma-gun, Japan, ²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: We have previously demonstrated that a combination of TNF-a and IL-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in…
Abstract Number: 1734 • ACR Convergence 2023
Serum PDGF-BB Levels Correlate with Lung Fibrosis in Mice Injected with Malondialdehyde-Acetaldehyde and/or Citrulline Modified Vimentin
Nozima Aripova¹, Michael Duryee¹, Carlos Hunter¹, Amy Nelson¹, Breanna Butler¹, Jill Poole¹, Bryant England¹, Geoffrey Thiele¹ and Ted R Mikuls², ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Pulmonary manifestations of rheumatoid arthritis (RA), such as interstitial lung disease (RA-ILD), are a major contributor to morbidity and mortality. The mechanism of pulmonary…
Abstract Number: 1750 • ACR Convergence 2023
Dysregulated NUB1 and Neddylation Enhances Rheumatoid Arthritis Fibroblast-Like Synoviocyte Inflammatory Responses
Sho Sendo¹, Camilla R. L. Machado², Robert Benschop³, Narayanan B. Perumal⁴, Eunice Choi⁵, David Boyle⁵, Wei Wang⁵ and Gary Firestein², ¹Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²University of California San Diego, San Diego, CA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Eli Lilly and Company, San Diego, CA, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Fibroblast-like synoviocytes (FLS) contribute to the pathogenesis of rheumatoid arthritis (RA), especially cartilage damage and cytokine production. These cells display an aggressive phenotype in…
Abstract Number: 1766 • ACR Convergence 2023
Inflammatory Priming of the Joints via Pre-activation of Macrophages by Anti-MAA Antibodies in Rheumatoid Arthritis
Marcelo Afonso¹, Jitong Sun¹, Koji Sakuraba¹, Anca Catrina¹, Aase Hensvold², Caroline Grönwall¹ and Bence Réthi¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet. Center for Rheumatology, Academic Specialist Center, Stockholm, Sweden
Background/Purpose: We have previously shown that certain malondialdehyde/acetaldehyde modified protein binding autoantibodies (anti-MAA), obtained from the inflamed joints of rheumatoid arthritis (RA) patients, induced osteoclast…
Abstract Number: 1857 • ACR Convergence 2023
More Than 50% of Rheumatoid Arthritis (RA) Patients with High or Moderate CDAI (clinical Disease Activity Index) Screen Positive on MDHAQ (multidimensional Health Assessment Questionnaire) Indices for FAST4 (fibromyalgia Assessment Screening Tool) And/or MDS2 (MDHAQ Depression Screen)
Juan Schmukler and Theodore Pincus, Rush University Medical Center, Chicago, IL
Background/Purpose: Treat to target in rheumatoid arthritis (RA) suggests escalation of therapy in patients whose scores are high or moderate on a disease activity index…
Abstract Number: 1923 • ACR Convergence 2023
Prevalence and Patterns of Comorbidities in Different Rheumatic Diseases: A Study from Tertiary Healthcare Centre
Smruti Ramteke¹, sanjay Ramteke² and Sandeep Yadav³, ¹Arthritis Clinic, Jasleen Hospital, Nagpur, India, ²Government Super Speciality Hospital Nagpur, Nagpur, India, ³P D Hinduja national Hospital and medical Research centre, Mumbai, India
Background/Purpose: The prevalence of comorbidities in rheumatic diseases may vary by disease and geographic region. This study aimed to investigate the comorbidities associated with rheumatoid…
Abstract Number: 2104 • ACR Convergence 2023
Relationship Between Frailty and Large Joint Symptoms in Rheumatoid Arthritis Patients
Yasumori Sobue¹, Mochihito Suzuki², yoshifumi Ohashi², Shuji Asai² and Shiro Imagama², ¹Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan, ²Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a causative factor in frailty. Large joint symptoms in RA patients may be more strongly associated with physical disability than…
Abstract Number: 2120 • ACR Convergence 2023
Independent and Combined Impact of Interstitial Lung Disease and Airway Disease on Rheumatoid Arthritis Disease Activity and Infections
Misaki Yoshida¹, takeshi Zoshima², Ichiro Mizushima² and Mitsuhiro Kawano², ¹Kanazawa University, Fukui, Japan, ²Kanazawa University, Kanazawa, Japan
Background/Purpose: How interstitial lung disease (ILD) and airway disease (AD) independently affect the clinical course of rheumatoid arthritis (RA) is unclear since previous studies conflated…
Abstract Number: 2136 • ACR Convergence 2023
Arthritogenic Cells Found in the Peripheral Blood of Rheumatoid Arthritis Patients Transfer the Disease to NSG-DR4 Mice
Janine Rupp¹, Johannes Fessler², Silvia Hayer³, Barbara Dreo⁴, Angelika Lackner², Patrizia Fasching², Wolfgang Helmberg², Peter Schlenke², Jens Thiel⁵, Guenter Steiner⁶, Cornelia M. Weyand⁷ and Martin Stradner², ¹Medical University Graz, Rochester, MN, ²Medical University of Graz, Graz, Austria, ³Medical University of VIenna, Vienna, Austria, ⁴Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁵University Hospital Freiburg, Freiburg, Germany, ⁶Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁷Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: T cells play an important role in the genesis of rheumatoid arthritis (RA). HLA class II genes, such as HLA-DRB1*0401 (HLA-DR4), confer the strongest…
Abstract Number: 2152 • ACR Convergence 2023
Survival Benefits of Knee and Hip Arthroplasty in Patients with Rheumatoid Arthritis: A General Population-based Cohort Study
Xinjia Deng¹, Yuqing Zhang², Yilun Wang¹, Na Lu³, Dongxing Xie⁴, Houchen Lyu⁵, Jie Wei⁶, Chao Zeng¹, Guanghua Lei¹ and Hui Li¹, ¹Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Xiangya Hospital, Central South University, Changsha, China, ⁵Chinese PLA General Hospital, Department of Orthopedics, Beijing, China, ⁶Health Management Center, Xiangya Hospital Central South University, Changsha, China
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risk of cardiovascular disease (CVD), venous thromboembolism (VTE), and mortality. Many patients with RA underwent knee and…
Abstract Number: 2169 • ACR Convergence 2023
Cost-utility of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-economic Analysis of the Towards the Lowest Efficacious Dose Trial
Joanna Kedra¹, Benjamin Granger², Lina El Houari³, Florence Tubach⁴ and Bruno Fautrel⁵, ¹Sorbonne Université, IPLESP, and Pitié-Salpêtrière Hospital, Paris, France, ²Sorbonne Université, INSERM, and Pitié Salpêtrière Hospital, Paris, France, ³Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France, ⁴Centre de pharmaco-épidémiologie de l'APHP, Paris, France, ⁵Sorbonne Université APHP, Paris, France
Background/Purpose: Biologic Disease Modifying Anti-Rheumatic Drugs (bDMARDs) progressive tapering is a real opportunity in people living with rheumatoid arthritis (RA) having achieved remission both from…
Abstract Number: 2438 • ACR Convergence 2023
Synovial Tissue Single-Cell Analysis Demonstrates Differential Fibroblast Populations Between RA and PsA Which Display Distinct Function
Órla Tynan¹, Mary Canavan², Achilleas Floudas³, Conor Smith⁴, Aoife O' Rourke⁴, Dumitru Anton⁵, Carl Orr⁶, Douglas Veale⁷ and Ursula Fearon⁸, ¹Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ²Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, School of Biochemistry & Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland, ³Dublin City University, Dublin, Ireland, ⁴Translational Immunology, Trinity Biomedical Sciences Institute, Dublin, Ireland, ⁵Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ⁶EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ⁷St.Vincent's University Hosp, Dublin, Ireland, ⁸Trinity College Dublin, Dublin, Ireland
Background/Purpose: Synovial fibroblasts (FLS) are key contributors to joint inflammation and damage in patients with Rheumatoid (RA) and Psoriatic Arthritis (PsA). Recent studies have identified…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].